

Mycosis Fungoides

Stage IIB

Indolent Disease

Aggressive Disease

Failed Systemic
 Therapy only

Failed both
 Methotrexate and
 Bexarotene

[LYMNHL0118](#)
 Phase II MK-3475
 in the Treatment of
 Relapsed/
 Refractory Mycosis
 Fungoides/Sezary
 Syndrome

Failed
 Systemic
 Therapy/topical

[LYMNHL0103](#)
 Phase III Safety
 and Efficacy of
 E7777 (Denileukin
 Diftitox) in
 Persistent/
 Recurrent
 Cutaneous NHL

- Large Cell
 Transformation (LCT)

[LYMNHL0095](#)
 Phase III Brentuximab
 Vedotin (SGN-35) vs
 Physician's Choice
 (Methotrexate/
 Bexarotene) in CD30+
 CTCL

[LYMNHL0103](#)
 Phase III Safety and
 Efficacy of E7777
 (Denileukin Diftitox) in
 Persistent/Recurrent
 Cutaneous NHL

PI: Kim
 CITN

No prior
 Romidepsin

PI: Kim
 Eisai Oncology
 Franchise

[LYMNHL0099](#)
 Phase III Monoclonal
 Antibody KW-0761
 (Mogamulizumab) Vs
 Vorinostat in
 Cutaneous T-Cell
 Lymphoma

PI: Kim
 Millennium Pharmaceuticals

PI: Kim
 Eisai Oncology Franchise

[LYMNHL0127](#)
 Phase I Dose-
 Escalation
 Carfilzomib +/-
 Romidepsin in
 Cutaneous T-Cell
 Lymphoma

PI: Kim
 Kyowa Hakkō Kirin
 Pharma

Failed Control Arm

[LYMNHL0095-EX](#)
 Treatment Option
 Brentuximab Vedotin in
 Progression of HD or
 Systemic Anaplastic Large
 Cell Lymphoma

PI: Kim
 Seattle Genetics

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Trial Posting
- Extension Study
- Enrollment on Hold